JP6607675B2 - 中胚葉系列の前駆細胞 - Google Patents

中胚葉系列の前駆細胞 Download PDF

Info

Publication number
JP6607675B2
JP6607675B2 JP2014517958A JP2014517958A JP6607675B2 JP 6607675 B2 JP6607675 B2 JP 6607675B2 JP 2014517958 A JP2014517958 A JP 2014517958A JP 2014517958 A JP2014517958 A JP 2014517958A JP 6607675 B2 JP6607675 B2 JP 6607675B2
Authority
JP
Japan
Prior art keywords
population
cells
pml
tissue
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014517958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520523A (ja
JP2014520523A5 (https=
Inventor
ハウゼ，トーマス，アヴェレル
エヴァンズ，マーティン，ジョン
レジナルド，アジャン
イーナ ローラ ピーパー
ブライアン リー パーキンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Therapy Ltd
Original Assignee
Cell Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1111509.4A external-priority patent/GB201111509D0/en
Priority claimed from GBGB1111500.3A external-priority patent/GB201111500D0/en
Priority claimed from GBGB1111503.7A external-priority patent/GB201111503D0/en
Priority claimed from GBGB1111505.2A external-priority patent/GB201111505D0/en
Application filed by Cell Therapy Ltd filed Critical Cell Therapy Ltd
Publication of JP2014520523A publication Critical patent/JP2014520523A/ja
Publication of JP2014520523A5 publication Critical patent/JP2014520523A5/ja
Application granted granted Critical
Publication of JP6607675B2 publication Critical patent/JP6607675B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
JP2014517958A 2011-07-06 2012-07-06 中胚葉系列の前駆細胞 Active JP6607675B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1111509.4 2011-07-06
GBGB1111509.4A GB201111509D0 (en) 2011-07-06 2011-07-06 Orthopedic MSC subtype
GBGB1111500.3A GB201111500D0 (en) 2011-07-06 2011-07-06 Wet age-related macular degeneration MSC subtype
GB1111505.2 2011-07-06
GB1111503.7 2011-07-06
GBGB1111503.7A GB201111503D0 (en) 2011-07-06 2011-07-06 Heart failure (HF) MSC subtype
GBGB1111505.2A GB201111505D0 (en) 2011-07-06 2011-07-06 MI MSC subtype
GB1111500.3 2011-07-06
PCT/GB2012/051600 WO2013005053A2 (en) 2011-07-06 2012-07-06 Progenitor cells of mesodermal lineage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017144116A Division JP2017225451A (ja) 2011-07-06 2017-07-26 中胚葉系列の前駆細胞

Publications (3)

Publication Number Publication Date
JP2014520523A JP2014520523A (ja) 2014-08-25
JP2014520523A5 JP2014520523A5 (https=) 2015-07-16
JP6607675B2 true JP6607675B2 (ja) 2019-11-20

Family

ID=46513785

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014517958A Active JP6607675B2 (ja) 2011-07-06 2012-07-06 中胚葉系列の前駆細胞
JP2017144116A Pending JP2017225451A (ja) 2011-07-06 2017-07-26 中胚葉系列の前駆細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017144116A Pending JP2017225451A (ja) 2011-07-06 2017-07-26 中胚葉系列の前駆細胞

Country Status (19)

Country Link
US (3) US10472609B2 (https=)
EP (1) EP2729562B1 (https=)
JP (2) JP6607675B2 (https=)
CN (2) CN107746830A (https=)
AU (2) AU2012279995C1 (https=)
CA (1) CA2840307C (https=)
CY (1) CY1120646T1 (https=)
DK (1) DK2729562T3 (https=)
EA (1) EA029577B1 (https=)
ES (1) ES2675693T3 (https=)
HR (1) HRP20181152T1 (https=)
HU (1) HUE039236T2 (https=)
IL (2) IL230071B (https=)
LT (1) LT2729562T (https=)
MY (1) MY185016A (https=)
PL (1) PL2729562T3 (https=)
PT (1) PT2729562T (https=)
SG (1) SG10201605518XA (https=)
WO (1) WO2013005053A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
CN112569259A (zh) * 2011-11-23 2021-03-30 细胞治疗有限公司 血小板裂解物凝胶
EP3052943B1 (en) * 2013-10-04 2019-11-20 Cell Ideas Pty Ltd. Biomarkers for cell therapy
GB201408712D0 (en) * 2014-05-16 2014-07-02 Univ Leuven Kath Mesodermal progenitor cells
GB201410504D0 (en) * 2014-06-12 2014-07-30 Cell Therapy Ltd Immuno-modulaltory progenitor (IMP) cell
EP3186614A4 (en) * 2014-08-29 2018-03-21 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
TWI723977B (zh) * 2015-02-20 2021-04-11 國立陽明大學 間質幹細胞於治療骨關節炎之用途
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
GB201513996D0 (en) * 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
CA2998096C (en) 2015-09-11 2024-01-30 Astellas Pharma Inc. Method for producing renal progenitor cells
GB201518263D0 (en) 2015-10-15 2015-12-02 Oxford Bioelectronics Ltd Method
CN105483206B (zh) * 2016-01-06 2019-09-13 北京汉氏联合生物技术股份有限公司 一种用vcam-1检测msc促内皮细胞增殖能力的方法
JP7177041B2 (ja) * 2016-08-29 2022-11-22 ハッケンサック ユニヴァーシティ メディカル センター 血小板様細胞を含有する血液の血小板に富む画分を用いて成体細胞をプログラミングするための組成物および方法
KR20190039822A (ko) * 2016-08-29 2019-04-15 해컨색 유니버시티 메디컬 센터 인간에서 혈소판-유사 세포를 함유하는 혈액의 혈소판 풍부 분획의 줄기세포능을 통해 성체 세포를 재프로그래밍하기 위한 조성물 및 방법
CN119033819A (zh) 2017-11-22 2024-11-29 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
JP7009977B2 (ja) 2017-12-25 2022-01-26 国立大学法人東海国立大学機構 被検体の血中ｖｅｇｆ－ａに関する測定値を用いた心疾患の重症度及び予後予測を行うための方法、装置及びコンピュータプログラム
CN108715833B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
KR102928332B1 (ko) * 2018-11-14 2026-02-19 온데르조엑스- 엔 온트윅켈링즈폰즈 로데 크루이스-플란데렌 혈소판 방출물의 제조방법
CN109329270A (zh) * 2018-11-19 2019-02-15 成都清科生物科技有限公司 一种静脉回输用间充质干细胞保存液及其制备方法
JP7558952B2 (ja) * 2019-01-15 2024-10-01 セル セラピー リミテッド 中胚葉キラー（ｍｋ）細胞
GB201900554D0 (en) 2019-01-15 2019-03-06 Cell Therapy Ltd Mesodermal killer (mk) cell
US20220160776A1 (en) * 2019-01-28 2022-05-26 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
TW202110463A (zh) * 2019-05-15 2021-03-16 美商永生生技股份有限公司 高濃度細胞包裝和運送
CN110237094B (zh) * 2019-07-30 2023-10-03 天晴干细胞股份有限公司 一种底层血小板因子贴及sPL血小板因子凝胶贴膜的制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
RU2138162C1 (ru) 1997-04-17 1999-09-27 Суханов Владимир Александрович Способ криоконсервации богатой тромбоцитами плазмы
CA2294944A1 (en) 1997-07-03 1999-01-14 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
AU9127098A (en) 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
PT1082410E (pt) 1998-05-29 2007-11-09 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas cd45+ e/ou fibroblastos+
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
EP2348104A1 (en) 1999-08-05 2011-07-27 Mcl Llc Multipotent adult stem cells and methods for isolation
JP2003055237A (ja) * 2001-08-15 2003-02-26 Japan Science & Technology Corp 骨再生促進剤
AUPR703601A0 (en) 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
EP1483371B1 (en) 2002-02-19 2007-06-27 Medipost, Co., Ltd. Isolation and culture-expansion methods of mesenchymal stem/progenitor cells from umbilical cord blood, and differentiation method of umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues
KR100534215B1 (ko) 2003-11-11 2005-12-08 (주)히스토스템 냉동 보관된 제대혈로부터 중간엽 줄기세포의 분리 및 배양 방법
DE102005011568A1 (de) 2004-04-13 2005-11-17 Man Roland Druckmaschinen Ag Produktionsverfahren für eine Prägeeinrichtung in einer Bogendruckmaschine
US20090047257A1 (en) 2004-07-20 2009-02-19 Case Western Reserve University Novel cell populations and uses thereof
KR20070085288A (ko) 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
CA2866468C (en) 2004-09-24 2019-09-03 Mesoblast, Inc. Generating multipotential expanded mesenchymal precursor cell progeny (memp) from mesenchymal progenitor cells (mpc) and stimulation factor
WO2006108229A1 (en) 2005-04-12 2006-10-19 Angioblast Systems, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
KR100679642B1 (ko) * 2005-11-16 2007-02-06 주식회사 알앤엘바이오 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
EP1845154A1 (en) 2006-04-12 2007-10-17 RNL Bio Co., Ltd. Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same
JP6041456B2 (ja) 2006-07-12 2016-12-07 メゾブラスト，インコーポレーテッド 過剰新生血管形成の治療
MY165114A (en) 2006-09-01 2018-02-28 Stempeutics Res Private Limited Self-renewing master adult pluripotent stem cells
WO2008097828A2 (en) 2007-02-02 2008-08-14 St. Jude Children's Research Hospital Method for isolating mesenchymal stromal cells
WO2008129563A2 (en) 2007-04-23 2008-10-30 Stempeutics Research Private Limited, Human mesenchymal stem cells and preparation thereof
US20090053182A1 (en) 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
EP2014294A1 (en) 2007-07-13 2009-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of CD200 as a mesenchymal stem cells marker
KR100970753B1 (ko) 2007-10-01 2010-07-16 재단법인서울대학교산학협력재단 광화능을 갖는 인간 치아 줄기세포 및 그의 배양방법
CA2692634C (en) 2007-11-09 2014-05-27 Rnl Bio Co., Ltd Method for isolating and culturing adult stem cells derived from human amniotic epithelium
KR101046188B1 (ko) * 2007-11-30 2011-07-04 주식회사 알앤엘바이오 탈락막 또는 지방 유래 줄기세포를 함유하는 요실금의 세포치료제
EP2297305A4 (en) 2008-05-15 2013-03-13 Univ Miami ISOLATION OF STEM CELL PROCESSORS AND EXPANSION UNDER NON-TERMS OF CONDITION
JP2011526892A (ja) 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療
EP2321408A4 (en) 2008-08-04 2013-04-17 Allocure Inc MESENCHYMAL STROMAZELL POPULATIONS AND PROCESS FOR THEIR INSULATION AND USE
EP2324359B1 (en) 2008-08-18 2018-10-31 Mesoblast, Inc. Use of heat shock protein 90-beta as marker for the identification and/or enrichment of adult multipotential mesenchymal precursor cells
JP5793724B2 (ja) * 2008-08-22 2015-10-14 公益財団法人ヒューマンサイエンス振興財団 脳梗塞治療材
ES2982461T3 (es) 2008-09-16 2024-10-16 Mayo Found Medical Education & Res Composiciones que contienen contenido plaquetario
EP2186883A1 (en) 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
EP2350266B1 (en) 2008-11-20 2015-07-29 Mesoblast, Inc. Method for treating or preventing a pancreatic dysfunction
JP5647230B2 (ja) 2009-04-28 2014-12-24 アントロジェン カンパニー リミテッドＡｎｔｅｒｏｇｅｎ Ｃｏ．， Ｌｔｄ． 瘻孔治療のための自家及び同種異系の脂肪由来間質幹細胞組成物
US20120276067A1 (en) 2009-10-13 2012-11-01 Allocure, Inc. Assay for the Prediction of Therapeutic Effectiveness of Mesenchymal Stromal Cells, and Methods of Using Same
ES2358146B1 (es) 2009-10-22 2012-03-23 Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla Uso de células mesenquimales nestina positivas para el mantenimiento de la hematopoyesis.
US20120269779A1 (en) 2009-10-30 2012-10-25 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
CN102048756B (zh) 2009-11-04 2014-02-19 中国医学科学院基础医学研究所 人脂肪来源的间充质干细胞在肾脏、眼底疾病中的用途
WO2011068792A2 (en) 2009-12-01 2011-06-09 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
EP2506867B1 (en) * 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
CA2803641A1 (en) 2010-07-02 2012-01-05 Mesoblast, Inc. Treatment of t-cell mediated immune disorders
EP2608797B1 (en) 2010-08-27 2015-09-23 University of Miami Bone marrow derived cd271 precursor cells for cardiac repair
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
ES2384790B1 (es) 2010-12-10 2013-05-20 Instituto De Salud Carlos Iii Células madre mesenquimales aisladas a partir de sangre periférica.
US20120288480A1 (en) 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
CN102078644A (zh) * 2011-03-08 2011-06-01 吉林大学 一种简便高效的自体富血小板血浆提取装置及提取方法
KR101967492B1 (ko) 2011-05-19 2019-04-09 메소블라스트, 아이엔씨. 비만 및/또는 대사 증후군을 치료하는 방법
KR101920277B1 (ko) 2011-06-03 2018-11-20 메소블라스트, 아이엔씨. 뇌졸중 증상을 치료하는 방법
WO2012162754A1 (en) 2011-06-03 2012-12-06 Mesoblast, Inc Methods of treating or preventing neurological diseases
KR101786862B1 (ko) 2011-07-04 2017-10-18 메소블라스트, 아이엔씨. 류마티즘성 질환을 치료 또는 예방하는 방법
CA2847575C (en) 2011-09-09 2021-10-19 Mesoblast, Inc. Method for increasing osteoblastic function
HK1202581A1 (en) * 2012-02-13 2015-10-02 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
US20150064141A1 (en) 2012-04-05 2015-03-05 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
US20130273011A1 (en) 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome

Also Published As

Publication number Publication date
CN104508124B (zh) 2017-11-17
WO2013005053A2 (en) 2013-01-10
HRP20181152T1 (hr) 2018-09-21
JP2014520523A (ja) 2014-08-25
LT2729562T (lt) 2018-07-25
MY185016A (en) 2021-04-30
WO2013005053A3 (en) 2013-06-13
DK2729562T3 (en) 2018-07-23
EP2729562B1 (en) 2018-04-18
PL2729562T3 (pl) 2018-10-31
US10472609B2 (en) 2019-11-12
US20210032600A1 (en) 2021-02-04
IL264455A (en) 2019-02-28
CN107746830A (zh) 2018-03-02
ES2675693T3 (es) 2018-07-11
US20150071886A1 (en) 2015-03-12
PT2729562T (pt) 2018-07-18
US10829739B2 (en) 2020-11-10
CY1120646T1 (el) 2019-12-11
EA201391773A1 (ru) 2014-11-28
AU2012279995A1 (en) 2014-01-23
AU2012279995C1 (en) 2019-10-24
EP2729562A2 (en) 2014-05-14
AU2017204559A1 (en) 2017-07-20
JP2017225451A (ja) 2017-12-28
AU2012279995B2 (en) 2017-03-30
CN104508124A (zh) 2015-04-08
CA2840307A1 (en) 2013-01-10
US11873513B2 (en) 2024-01-16
US20200048613A1 (en) 2020-02-13
EA029577B1 (ru) 2018-04-30
SG10201605518XA (en) 2016-08-30
HUE039236T2 (hu) 2018-12-28
CA2840307C (en) 2021-10-19
IL230071B (en) 2019-02-28
NZ620283A (en) 2016-06-24

Similar Documents

Publication Publication Date Title
JP6607675B2 (ja) 中胚葉系列の前駆細胞
JP6185657B2 (ja) 免疫調節前駆（ｉｍｐ）細胞
EP1458854B1 (en) Cellular compositions and methods of making and using them
CA2556018A1 (en) Stem cell populations and methods of use
WO2003035838A2 (en) Stem cells that transform to beating cardiomyocytes
EP3154599B1 (en) Hybrid composition
KR20180057614A (ko) 면역-종양학 중배엽 전구체(iomp) 세포
WO2009152186A1 (en) Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
NZ620283B2 (en) Progenitor cells of mesodermal lineage
HK1198047B (en) Progenitor cells of mesodermal lineage
HK1198047A (en) Progenitor cells of mesodermal lineage
Larson Characterization of Stromal Cells Derived from Bone Marrow, Dermis, and Myocardium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191021

R150 Certificate of patent or registration of utility model

Ref document number: 6607675

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250